Tratopedia
繁中
Settings

Text size

Language

Theme

High contrast

Version

v1.230.2

The release this page was built from. It is what the service worker caches under.

Spatial Transcriptomics · Intellectual Property · Corporate Restructuring · Bruker · Business ReportSources read 17 October 2026

Three companies, one division, one unanswered question

Bruker’s spatial biology division: NanoString, Canopy and Acuity

Bruker Spatial Biology, formed on 9 October 2024, puts three businesses under one division of Bruker’s BSI NANO segment: NanoString, bought out of Chapter 11 for $392.6 million in May 2024; Canopy Biosciences, bought in 2020; and Bruker Spatial Genomics, the renamed Acuity Spatial Genomics that Bruker founded with Harvard technology in 2021. A fourth, Bruker Cellular Analysis, joined on 1 April 2026. Between them they measure DNA folding, RNA, protein and live-cell behaviour in tissue. NanoString collapsed under a patent war with 10x Genomics and years of losses; Bruker settled that war in May 2025 for $68.0 million plus royalties. What is not known is whether the division makes money: Bruker publishes no division revenue, took goodwill impairments touching it in late 2025 and mid-2026, and its finance chief said in August 2026 that it was still losing money.

What is established, and how firmly Each item with its standing first, read at the companies’ filings and releases.

  • $392.6Mcash Bruker paid for NanoString’s business, 6 May 2024
  • $68.0Msettlement with 10x Genomics, in four quarterly instalments, plus royalties on GeoMx and CosMx
  • $36.5Mgoodwill impairment on the division alone, second quarter of 2026
  • $174.5Mthe division’s goodwill left after that charge
StandingWhatRead at
Confirmed: filingNanoString filed for Chapter 11 in Delaware on 4 February 2024. Bruker won the auction on 16 April 2024 and closed on 6 May 2024 at $392,555,000 cash, 78.4% above the $220 million stalking-horse bid.NanoString Form 8-Ks of 5 Feb, 19 Apr and 6 May 2024
Confirmed: filingOn 17 November 2023 a Delaware jury found NanoString wilfully infringed seven 10x Genomics patents with GeoMx and awarded about $31 million.NanoString Form 8-K, 20 Nov 2023
Confirmed: filingOn 12 May 2025 Bruker and 10x settled every case in every jurisdiction: $68.0 million in four quarterly instalments from the third quarter of 2025, the last paid by 30 June 2026, plus royalties on GeoMx and CosMx sales for the life of the patents.10x Form 8-K, 14 May 2025; Bruker Form 10-Q, Q2 2026
Confirmed: filingBruker bought Canopy Biosciences on 10 September 2020 for $24.2 million, with up to $5.0 million more tied to 2021 and 2022 revenue.Bruker Form 10-Q, Q3 2020
Confirmed: filingGoodwill impairments: $96.5 million in the third quarter of 2025 across the division and an automation unit, not split; $36.5 million on the division alone in the second quarter of 2026, leaving $174.5 million.Bruker Form 10-Qs, Q3 2025 and Q2 2026
Confirmed: filingBruker Cellular Analysis, the former PhenomeX, was merged into the division on 1 April 2026.Bruker Form 10-Q, Q2 2026
Confirmed: company releaseBruker formed the division on 9 October 2024 from NanoString, Canopy and Bruker Spatial Genomics, the renamed Acuity, in “operational coordination”, with Todd Garland as president.Bruker press release, 9 Oct 2024
Confirmed: company releaseAcuity Spatial Genomics was formed in March 2021 with a majority investment by Bruker and an exclusive Harvard licence; Bruker’s Mark Munch was its CEO.SelectScience, 23 Mar 2021
Company target, not an outcomeAt the deal, Bruker said that by 2026 it expected NanoString to be “near break-even”. In August 2026 its finance chief said the spatial business “continued to experience operating losses”.Bruker exhibit, 22 Apr 2024; Q2 2026 call transcript
Company expectationShipments of the PaintScape 3D-genome instrument were expected from the second quarter of 2026 and of CellScape XR in summer 2026; no text read confirms either.Bruker releases, 23 Feb and 17 Apr 2026
Not publicThe division’s revenue and profit. Bruker reports only the BSI NANO segment, which also sells X-ray, atomic force microscopy and semiconductor metrology tools: $1,084.3 million in 2025.Bruker Form 10-K, 2025

What is settled

Who owns what, what was paid for it, how the litigation ended and what the settlement costs in cash are all in filings.

What is not

Whether the division is near break-even, how large it is, and whether the 2026 instruments shipped on time.

Twenty-three years, three companies Dated by the document that carries each item.

  1. Jun 2003NanoString is incorporated in Delaware, on barcode-counting technology conceived in Leroy Hood’s laboratories at the Institute for Systems Biology, Seattle; an exclusive licence follows in 2004.
  2. Oct 2008The first nCounter system is sold.
  3. 2013NanoString’s shares are approved for listing on Nasdaq as NSTG; its accumulated deficit is $102.8 million at 31 March 2013.
  4. Late 2016Canopy Biosciences is founded in St. Louis by the investor BioGenerator.
  5. 2019GeoMx Digital Spatial Profiler is launched.
  6. 10 Sep 2020Bruker acquires Canopy Biosciences ($24.2 million, up to $5.0 million more).
  7. 23 Mar 2021Acuity Spatial Genomics announces its formation and a majority investment by Bruker.
  8. 6 May 202110x Genomics sues NanoString in Delaware over GeoMx; a second suit, over CosMx, follows on 28 February 2022, and a Munich suit on 9 March 2022.
  9. 3 Mar 2022Canopy launches CellScape, the Bruker-designed next generation of its ChipCytometry instrument.
  10. Dec 2022CosMx Spatial Molecular Imager and the AtoMx cloud platform are launched.
  11. 17 May 2023The Munich Regional Court enjoins CosMx RNA products in Germany, from 1 June.
  12. 19 Sep 2023The Unified Patent Court’s Munich division issues a preliminary injunction on CosMx RNA products across its 17 member states.
  13. 2 Oct 2023Bruker completes its purchase of PhenomeX, agreed on 17 August at $1.00 a share; it is renamed Bruker Cellular Analysis.
  14. Oct 2023NanoString cuts about 110 positions, about 20% of its workforce.
  15. 17 Nov 2023Delaware jury verdict against GeoMx, about $31 million; on 19 November NanoString withdraws its 2023 guidance.
  16. 31 Dec 2023A second cut: about 50 positions, about 9%.
  17. 4 Feb 2024NanoString files for Chapter 11; Nasdaq suspends trading in its shares on 14 February.
  18. 26 Feb 2024The UPC Court of Appeal lifts the preliminary injunction; CosMx sales resume in 16 countries.
  19. 16 Apr 2024Bruker wins the auction against a $220 million stalking-horse bid; the court approves on 19 April.
  20. 6 May 2024The sale closes at $392,555,000; Bruker takes on $44.7 million of litigation liability.
  21. 9 Oct 2024Bruker Spatial Biology is formed.
  22. 23 Dec 202410x announces a US permanent injunction against GeoMx, sparing customers who installed before 18 November 2023.
  23. 21 Feb 2025At AGBT 2025: a CosMx whole-transcriptome panel (over 18,000 RNA transcripts) and PaintScape for the 3D genome.
  24. 12 May 2025Global settlement with 10x: $68.0 million plus royalties.
  25. Aug 2025Bruker announces $100–120 million of annual cost savings for 2026, later raised to $140 million.
  26. Q3 2025$96.5 million goodwill impairment across the division and an automation unit.
  27. 23 Feb 2026At AGBT 2026: CellScape XR, a mouse whole-transcriptome assay, PaintScape pre-orders, and a Glasgow centre of excellence.
  28. 1 Apr 2026Bruker Cellular Analysis merges into the division.
  29. Apr 202610x announces Atera, a whole-transcriptome in situ platform; at AACR on 17 April, Bruker shows workflows linking GeoMx, CellScape XR and CosMx on one section.
  30. Q2 2026$36.5 million impairment on the division; the last settlement instalment is paid.
  31. 1 Jul 2026Bruker reorganises into four groups; the BSI NANO segment, home of the division, is unchanged.
  32. Sep 202610x begins commercial shipments of Atera, with more than 40 instruments booked.

What cannot be dated. Whether PaintScape, CellScape XR and the mouse whole-transcriptome assay shipped when Bruker expected; whether the NanoString business came “near break-even” in 2026; how the $96.5 million charge of late 2025 divided between the division and the automation unit; and when Bruker will report its third quarter of 2026. None of the documents read settles any of them.

A sound technology business that could not pay for its own war What the filings show, what Bruker argues, and where the two meet.

  • Losses

    Revenue grew; the losses never closed

    • 2022: revenue $127.3 million, net loss $159.5 million.
    • Nine months of 2023: revenue $128.1 million, net loss $122.3 million; about $168 million for the full year, by Bruker’s count.
    • Accumulated deficit at 30 September 2023: $931.6 million.
  • Litigation

    Four years, three court systems

    • Injunctions in Germany (May 2023) and across the Unified Patent Court states (September 2023) hit CosMx.
    • The November 2023 jury verdict on GeoMx came with a guidance withdrawal two days later.
    • Bruker inherited the cases and settled them in May 2025.
  • Assembly

    Three routes into one division

    • Canopy: an acquisition, in 2020.
    • Acuity: a venture Bruker formed itself, in 2021.
    • NanoString: a bankruptcy purchase, in 2024.

Bruker’s case. When it bought NanoString, Bruker said it expected the business “to have rebounded and to be near break-even” by 2026, helped by not taking on NanoString’s public-company overhead, and the combined spatial business to grow at double-digit organic rates from 2027. Mark Munch, president of the Bruker NANO group, argued in October 2024 for “fit-for-purpose” platforms kept apart, each with its own team: “The road to failure, and the road to mediocrity, is to try to make a Swiss Army knife.” When 10x launched Atera in 2026, chief executive Frank Laukien said it was “remarkable to read that someone invented what we did a year ago”. These are a buyer’s and a competitor’s claims. The settlement is not a claim: 10x booked $40.7 million of the $68.0 million as a gain and $27.3 million as licence revenue, and the royalties on GeoMx and CosMx continue for the life of the patents.

  • $40.7Mof the settlement booked by 10x as a gain
  • $27.3Mbooked by 10x as licence and royalty revenue

A reading

Reading. NanoString did not fail for want of products: its revenue rose every year shown. It failed because the losses never closed while a patent war it was losing ran in three court systems at once; the verdict and the withdrawn guidance came eleven weeks before the bankruptcy. Bruker bought the products without the overhead and the war, and the price of ending the war is a royalty on two of the three spatial platforms for as long as the patents run.

What the division sells, and what the numbers can and cannot say Specifications are the maker’s; figures are from filings unless marked.

PlatformFromWhat it measuresScale
CosMx SMINanoStringRNA and protein in tissue: a human panel of over 18,000 transcripts plus 64+ proteins on one section; a mouse panel announced for 2026single cell, subcellular
GeoMx DSPNanoStringwhole transcriptome and more than 1,200 protein targets in regions the researcher selectsregions of tissue
nCounterNanoStringgene expression by direct barcode counting, up to 800 genes per runbulk sample
CellScape XRCanopyprotein, by repeated staining; a 208-plex dataset across 12 human tissues shown in 2026subcellular
PaintScapeAcuityhow chromosomes fold in the nucleus: a 419-plex panel; a 1000+-plex cancer panel promised for later in 2026single nucleus, 3D
BeaconPhenomeXwhat live cells do; paired with CosMx in a 2026 head and neck cancer studysingle live cell
AtoMx SIPNanoStringcloud analysis for CosMx: 3D AI cell segmentation, exports for large language modelssoftware

Where the pieces came from. Canopy reached CellScape through a German subsidiary, Zellkraftwerk, whose ChipCytometry instrument had been in use since 2016; Canopy’s 2022 launch release calls CellScape the next generation of it, designed with Bruker’s microscopy expertise. Munch describes Canopy as having had no instrument when Bruker bought it; the two Bruker accounts differ, and the earlier instrument is on record. Acuity licensed Oligopaint-based methods from Ting Wu’s laboratory at Harvard Medical School, published in Nature Methods in 2020; two of her postdoctoral researchers, Huy Q. Nguyen and Shyamtanu Chattoraj, were cofounders. PhenomeX, itself a 2023 merger of two single-cell companies, cost Bruker $109.4 million net of cash and was booked at a $144.1 million bargain-purchase gain; in December 2025 Bruker settled a patent dispute over Beacon with an antibody-discovery company for $36.0 million plus royalties. In February 2026 Bruker announced a centre of excellence at the University of Glasgow that is to image more than 1,000 pancreatic cancer samples on CellScape, CosMx and GeoMx. For the software that reads CosMx and GeoMx data, see six single-cell analysis platforms, compared.

FigureValueRead at
Bruker revenue, 2025$3.44 billion; organically −3.7%Results release, 12 Feb 2026
BSI NANO segment, 2025$1,084.3 million; 31.6% of BrukerForm 10-K, 2025
BSI NANO segment, first half 2026about $507 million; low single-digit declineQ2 2026 call
Bruker revenue, Q2 2026$838.5 million; organically +2.8%Results release, 4 Aug 2026
Bruker guidance, 2026$3.54–3.57 billion; organically +1–2%Results release, 4 Aug 2026
Bruker revenue from China, first half 2026$178.9 million, against $215.9 million (−17.1%)Form 10-Q, Q2 2026
Cost savings, 2026$140 million annualised; $30 million in Q2Q2 2026 call
10x Genomics revenue, 2025$642.8 million, of which $46.1 million licence and royalty10x Form 10-K, 2025
Spatial biology market, forecast~$1.14 billion in 2026; ~17% a year to ~$2.46 billion in 2031DeciBio report page, 2025

The competition. 10x Genomics, the other party to the litigation, reported $642.8 million of revenue in 2025, $301.9 million in the first half of 2026. It announced Atera, a whole-transcriptome in situ platform, in April 2026, and an investment-research summary reported shipments under way by late September with more than 40 instruments booked. Munch said in 2024 that CosMx “has always led in plex”; Laukien said in 2026 that Bruker is “still very much ahead”. No independent head-to-head comparison was read for this piece, so neither claim is tested here. GEN’s 2026 ranking puts three other public companies and several private ones in the field; the largest private competitor has raised more than $300 million, and another public company’s spatial segment, at $336.4 million for its last fiscal year, is subject to an announced $11.3 billion takeover. Funding is the pressure on all of them: GEN reports about $783 million of NIH grants cut, and Bruker says US academic demand stayed soft in the second quarter of 2026 while biopharma bookings across the company rose more than 20%.

The $1.084 billion is the segment

The figure ranked first in GEN’s 2026 list is BSI NANO’s whole revenue, and GEN labels it so. That segment also sells X-ray, atomic force microscopy and semiconductor metrology tools, and Bruker discloses nothing for the spatial division within it.

Specifications are the maker’s

“Best-in-class”, “first and only” and “highest fidelity” are Bruker’s words in its own releases. Plex counts and transcript numbers are what the panels are designed to detect, not independent measurements.

The broadest kit in the field, and no proof yet that it pays What follows from the record, and what to watch.

What the record supports

Reading. The division’s breadth is real and documented: DNA folding, region-level and single-cell RNA, protein and live-cell function, from one owner, with workflows that pass one tissue section between instruments. The settlement removed the legal risk to buyers of GeoMx and CosMx, at the cost of a lasting royalty.

What it does not

Reading. Nothing public shows the division making money. The only evidence on profitability is two impairments nine months apart and a finance chief’s August 2026 statement of continuing operating losses, and both point the same way. Bruker’s April 2024 target, “near break-even” by 2026, has not been reported met or missed.

  • Reading. For a laboratory choosing an instrument: the patent risk around GeoMx and CosMx ended with the 2025 settlement. Run the same tissue on the platforms being considered, since no independent comparison of CosMx and Atera was found, and ask for written commitments on consumables and cloud software, which depend on the division continuing in its present form.
  • Reading. For anyone sizing the business: do not use the $1.084 billion; it is the whole segment. The division-level evidence is the goodwill note in each Bruker 10-Q, which says what the division is worth on Bruker’s own books.
  • What to watch: Bruker’s third-quarter and full-year 2026 reports, for any further impairment and any word on break-even; whether PaintScape, CellScape XR and the mouse whole-transcriptome assay are reported shipping; and the first published comparisons of Atera and CosMx on the same tissue.

Hold loosely

Shipment dates are expectations; the break-even target is a target; the market forecast is one research seller’s, on its own definition; and Bruker’s and 10x’s claims about each other are competitors’ claims. Figures stand as they did on 17 October 2026.

Quick notes

  1. Research summary · 17 October 2026

    Bruker’s spatial biology map

    How NanoString, Canopy Biosciences and Acuity Spatial Genomics became one division, and where it stands

    Sources read 17 October 20261 / 15

  2. Basics

    What does spatial biology do?

    Not only which molecules are in a tissue, but where they are and what is next to them.

    • DNA

      How the genome folds

      • Where chromosomes and genes sit in the nucleus, in 3D.
      • At Bruker: PaintScape.
    • RNA

      Which genes are in use

      • Gene activity, with each cell’s position kept.
      • At Bruker: CosMx, GeoMx, nCounter.
    • Protein

      What does the work

      • The molecules that carry out a cell’s functions.
      • At Bruker: CellScape, plus GeoMx and CosMx panels.

    An analogy: blending a fruit salad tells you what was in it; spatial biology photographs the bowl first, then labels every piece.2 / 15

  3. Structure

    Four businesses, one division

    Bruker Spatial Biology, formed 9 October 2024, sits in Bruker’s BSI NANO segment. Its president is Todd Garland.

    BusinessBaseHow it joined
    NanoStringSeattle areabought out of bankruptcy, May 2024
    Canopy BiosciencesSt. Louisacquired, September 2020
    Bruker Spatial GenomicsSan Joseformerly Acuity; Bruker majority investment, 2021
    Bruker Cellular Analysis—formerly PhenomeX; merged in 1 April 2026

    “Bruker Spatial Genomics” is the renamed Acuity, not the division. Sources: Bruker release, 9 Oct 2024; Form 10-Q, Q2 2026.3 / 15

  4. NanoString, 2003–2013

    Counting RNA one barcode at a time

    1. 2003Incorporated, on technology conceived in Leroy Hood’s laboratories at the Institute for Systems Biology.
    2. 2004Exclusive worldwide licence: 13 patents and applications, low single-digit royalties.
    3. 2008First nCounter sold: up to 800 genes per run, counted directly.
    4. 2013Approved for listing on Nasdaq as NSTG; accumulated deficit already $102.8 million.
    5. Mar 2023About 1,130 nCounter systems installed; more than 6,820 papers.

    An analogy: each RNA gets its own coloured barcode, and the machine counts the barcodes. Position is lost; that came later. Sources: S-1/A, 2013; Form 10-Q, Q1 2023.4 / 15

  5. NanoString, the spatial turn

    GeoMx and CosMx

    Two instruments for two scales; AtoMx, the cloud software, launched with CosMx in December 2022.

    • 2019

      GeoMx DSP

      • The researcher selects regions of a tissue section; RNA and protein are profiled per region.
      • Now: whole transcriptome and more than 1,200 protein targets.
    • Dec 2022

      CosMx SMI

      • Single-cell and subcellular imaging of RNA and protein.
      • Since 2025: a human whole-transcriptome panel, over 18,000 transcripts, plus 64+ proteins on one section.

    An analogy: GeoMx circles a few districts on a map; CosMx is the satellite photo that shows who lives in each house. Sources: Form 10-Q, Q1 2023; Bruker releases, 2025 and 2026.5 / 15

  6. Litigation

    The patent war with 10x Genomics

    Four years across US, German and European patent courts.

    1. 6 May 202110x sues over GeoMx in Delaware.
    2. 17 May 2023Munich court enjoins CosMx RNA products in Germany.
    3. 19 Sep 2023Unified Patent Court preliminary injunction, 17 states.
    4. 17 Nov 2023Delaware jury: wilful infringement by GeoMx, about $31 million.
    5. 26 Feb 2024Appeal court lifts the UPC injunction; CosMx back in 16 countries.
    6. 23 Dec 2024US permanent injunction against GeoMx announced; earlier customers spared.
    7. 12 May 2025Global settlement: $68.0 million in four instalments, plus royalties for the life of the patents.

    Reading: the verdict, and the withdrawn guidance two days later, came eleven weeks before NanoString’s bankruptcy. Sources: 10x Form 8-K, May 2025, and Form 10-Q, Q1 2024; NanoString Form 8-K, Nov 2023.6 / 15

  7. 2023–2024

    Bankruptcy, and a buyer

    Revenue reached about $168 million in 2023; the losses did not close.

    • $127.3Mrevenue, 2022, against a net loss of $159.5M
    • $931.6Maccumulated deficit, 30 Sep 2023
    • $220Mstalking-horse bid, March 2024
    • $392.6MBruker’s winning cash bid, 78.4% higher
    • Two cuts: about 110 jobs in October 2023 and about 50 in December 2023.
    • Chapter 11 on 4 February 2024; auction on 16 April; closing on 6 May. Bruker also took on $44.7 million of litigation liability.

    Chapter 11 lets a company keep operating under court supervision and sell its assets to the best bidder. Sources: NanoString results and filings, 2023–2024; Bruker exhibit, Apr 2024.7 / 15

  8. Canopy Biosciences

    Seeing proteins in place

    Bought almost four years before NanoString; it brings the protein layer.

    1. Late 2016Founded in St. Louis by BioGenerator; chief executive Edward Weinstein.
    2. 2019A funding round pays for buying Zellkraftwerk, maker of a ChipCytometry instrument in use since 2016.
    3. 10 Sep 2020Bruker buys Canopy: $24.2 million, up to $5.0 million more.
    4. 3 Mar 2022CellScape launched, the next generation, designed with Bruker’s microscopy expertise.
    5. Feb 2026CellScape XR announced; shipments expected in summer 2026.

    An analogy: the same slide is stained, imaged and cleared again and again, one set of markers at a time, and the layers are stacked into one map. Sources: Bruker 10-Q, Q3 2020; BioSTL; Canopy release, 2022.8 / 15

  9. Acuity Spatial Genomics

    Seeing the genome in 3D

    The youngest piece; it brings the DNA layer.

    • March 2021: formed with a Bruker majority investment; Bruker NANO’s Mark Munch is chief executive; cofounders Huy Q. Nguyen and Shyamtanu Chattoraj.
    • Technology licensed from Ting Wu’s laboratory at Harvard Medical School, published in Nature Methods in 2020.
    • It sees chromosome folding, gene positions in the nucleus, and copy-number changes, in place.
    • PaintScape launched at AGBT in February 2025; pre-orders opened in 2026, with shipments expected from the second quarter of 2026.

    An analogy: DNA in the nucleus is not a straight line but a folded ball of wool; which strands touch affects which genes switch on. Sources: SelectScience, Mar 2021; Bruker releases, 2025 and 2026.9 / 15

  10. 9 October 2024

    Forming Bruker Spatial Biology

    Coordinate first; do not break the businesses up.

    • “Fit-for-purpose”: CosMx, GeoMx and CellScape keep their own teams. Munch: “The road to failure … is to try to make a Swiss Army knife.”
    • Each business stays where it was: Seattle, St. Louis, San Jose.
    • Leadership: Todd Garland, president; Joseph Beechem, NanoString’s founding chief scientific officer, held the title at the division in 2025.
    • 1 April 2026: Bruker Cellular Analysis joins. 1 July 2026: Bruker reorganises into four groups; the division’s segment is unchanged.

    An analogy: specialist shops brought into one department store, each counter still run by its own staff. Sources: Bruker release, 9 Oct 2024; GEN, 11 Oct 2024; Form 10-Q, Q2 2026.10 / 15

  11. Portfolio

    The product map today

    DNA, RNA, protein and live cells under one owner.

    PlatformMeasuresScale
    CosMxRNA and protein; human and mouse whole transcriptomesingle cell, subcellular
    GeoMxwhole transcriptome, 1,200+ proteinsselected regions
    CellScape XRhigh-plex proteinsubcellular
    PaintScape3D structure of DNAin the nucleus
    nCountergene expression, up to 800 genesbulk
    Beaconlive-cell functionsingle cell
    AtoMxcloud analysis, 3D AI segmentationsoftware

    2026: workflows linking GeoMx to CellScape XR and CellScape XR to CosMx on one tissue section; a Glasgow centre is to image 1,000+ pancreatic cancer samples. Sources: Bruker releases, Feb and Apr 2026.11 / 15

  12. Money

    Broad technology, unproven profit

    Bruker does not report the division’s revenue; this is what the filings do show.

    • $96.5Mgoodwill impairment, Q3 2025, division and an automation unit together
    • $36.5Mgoodwill impairment, Q2 2026, the division alone
    • $174.5Mdivision goodwill left after it
    • Target set in April 2024: NanoString “near break-even” by 2026. August 2026: the business “continued to experience operating losses”.
    • The $1.084 billion often quoted for 2025 is the whole BSI NANO segment, including X-ray, atomic force microscopy and semiconductor metrology; the division’s revenue is not disclosed.

    Goodwill is the premium paid over a business’s identifiable assets; an impairment writes it down when the business is worth less than its book value. Sources: Bruker 10-Qs, Q3 2025 and Q2 2026; exhibit, Apr 2024; Q2 2026 call.12 / 15

  13. Competition

    Who else is in the field

    10x Genomics is the litigant and the reference rival; Bruker’s case rests on breadth.

    CompanySpatial platformsScale
    10x GenomicsVisium HD, Xenium, Atera (shipping from Sep 2026)$642.8M revenue, 2025, incl. $46.1M licence and royalty
    Bruker Spatial BiologyCosMx, GeoMx, CellScape XR, PaintScape, nCounternot disclosed
    A diagnostics and reagents groupa diagnostics and spatial biology segment$336.4M segment, last fiscal year; $11.3B takeover announced
    A proteomics-imaging companymultiplex protein imaging$69.2M spatial revenue, 2025
    The largest private competitorimaging spatial transcriptomicsmore than $300M raised

    “CosMx has always led in plex” is Bruker’s claim; Atera now challenges CosMx’s whole-transcriptome position. No independent comparison was read. Sources: 10x 10-K, 2025; GEN, 9 Oct 2026; Zacks, 30 Sep 2026.13 / 15

  14. Outlook

    What is Bruker betting on?

    One market report puts spatial biology at ~$1.14 billion in 2026, growing ~17% a year; definitions differ between reports.

    • Opportunities

      What could work

      • Biopharma bookings across all of Bruker up more than 20% in Q2 2026.
      • Reading: one tissue passed between instruments could make the platforms hard to swap out.
      • Roadmap: CosMx miRNA and TCR assays; a 1000+-plex PaintScape cancer panel.
    • Risks

      What could go wrong

      • US academic funding: soft demand reported through Q2 2026.
      • 10x’s scale and Atera; the royalty on GeoMx and CosMx.
      • China: Bruker’s revenue there down 17.1% in the first half of 2026; further impairments, which Bruker’s 10-Q says may be incurred.

    Sources: Q2 2026 call; Bruker releases, 2026; Form 10-Q, Q2 2026; DeciBio, 2025.14 / 15

  15. In one slide

    The whole story

    NanoString fell to a patent war and years of losses and was bought by Bruker; Canopy and Acuity add the protein and DNA layers. The breadth is real; the profit is not yet shown.

    • Watch: Bruker’s third-quarter and full-year 2026 reports, for impairments and any word on break-even.
    • Watch: whether PaintScape, CellScape XR and the mouse whole-transcriptome assay are reported shipping.
    • Watch: the first published comparisons of Atera and CosMx on the same tissue.
    • Reading, for laboratories: the patent risk is gone; test on your own tissue and get consumables and software commitments in writing. For analysts: do not use the $1.084 billion as the division’s revenue.

    Bruker’s spatial biology division · sources read 17 October 202615 / 15

  • Bruker, press releases of 11 Sep 2020 and 9 Oct 2024
  • Canopy Biosciences, release of 3 Mar 2022
  • BioSTL on the Canopy acquisition
  • Bruker, Forms 10-Q for Q3 2020, Q3 2025 and Q2 2026, Form 10-K for 2025, and results releases of 12 Feb, 6 May and 4 Aug 2026, SEC EDGAR
  • Bruker, exhibit of 22 Apr 2024 on the NanoString deal and the PhenomeX agreement of 17 Aug 2023, SEC EDGAR
  • Bruker Spatial Biology, AGBT releases of 21 Feb 2025 and 23 Feb 2026 and AACR release of 17 Apr 2026 (Business Wire, via Yahoo Finance)
  • Bruker Cellular Analysis, blog of 6 Feb 2026
  • NanoString, Form S-1/A (2013), Forms 10-Q for Q1 and Q3 2023, Forms 8-K of 20 Nov 2023, 5 Jan, 5 Feb, 19 Apr and 6 May 2024, SEC EDGAR
  • NanoString, results release of 28 Feb 2023 and UPC appeal release of 26 Feb 2024
  • 10x Genomics, Form 8-K of 14 May 2025, Forms 10-Q for Q1 2024 and Q3 2025 and Form 10-K for 2025, SEC EDGAR
  • 10x Genomics, release of 23 Dec 2024 (PR Newswire) and the Atera release of Apr 2026
  • SelectScience, 23 Mar 2021
  • GEN, 11 Oct 2024 and 9 Oct 2026
  • The Motley Fool, transcripts of Bruker’s Q1 and Q2 2026 calls
  • Zacks Equity Research, 30 Sep 2026 (via Yahoo Finance)
  • DeciBio, spatial biology market report page. Read 17 October 2026.

Versions

This document is rewritten when what it says has to change. Every version stays published at its own address.

  1. v0001 current

The current version is also at latest/.